Versant Venture Capital Vi, L.P. Graphite Bio, Inc. (GRPH) insider trading activity

Versant Venture Capital Vi, L.P. is of Graphite Bio, Inc.. Currently has a direct ownership of 1.27 Million shares of GRPH, which is worth approximately $0. The most recent transaction as insider was on Aug 26, 2025, when has been sold 47,443 shares (Common Stock) at a price of $39.24 per share, resulting in proceeds of $1,861,663. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.27M

91.34% 3M change

91.34% 12M change

Total Value Held $0

Versant Venture Capital VI, L.P. Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 26 2025	SELL Open market or private sale	$1,861,663 $39.24 p/Share	47,443 Reduced 3.59%	1,274,197 Common Stock
Aug 25 2025	SELL Open market or private sale	$2,082,082 $39.72 p/Share	52,419 Reduced 3.81%	1,321,640 Common Stock
Aug 22 2025	SELL Open market or private sale	$1,054,549 $40.31 p/Share	26,161 Reduced 1.87%	1,374,059 Common Stock
Aug 18 2025	SELL Open market or private sale	$1,181,015 $38.56 p/Share	30,628 Reduced 2.14%	1,400,220 Common Stock
Aug 15 2025	SELL Open market or private sale	$5,729,514 $39.5 p/Share	145,051 Reduced 9.2%	1,430,848 Common Stock
Jul 10 2025	SELL Open market or private sale	$6,506,784 $34.0 p/Share	191,376 Reduced 10.83%	1,575,899 Common Stock
Jun 27 2025	SELL Open market or private sale	$6,092,000 $30.46 p/Share	200,000 Reduced 10.17%	1,767,275 Common Stock
Jun 20 2025	SELL Open market or private sale	$4,051,201 $30.25 p/Share	133,924 Reduced 6.37%	1,967,275 Common Stock
Jun 29 2021	BUY Conversion of derivative security	-	12,343,727 Added 45.63%	14,708,398 Common Stock

Also insider at

BDTX

Black Diamond Therapeutics, Inc. Healthcare

ALGS

Aligos Therapeutics, Inc. Healthcare

> 10% Shareholder

OYST

Oyster Point Pharma, Inc. Healthcare

> 10% Shareholder

IPSC

Century Therapeutics, Inc. Healthcare

> 10% Shareholder

GLUE

Monte Rosa Therapeutics, Inc. Healthcare

CTNM

Contineum Therapeutics, Inc.

> 10% Shareholder

TPST

Tempest Therapeutics, Inc. Healthcare

VVC